Evidence map›Paper›PMID 35529920›Full record

ArticleEvidence-based complementary and alternative medicine : eCAM2022

Safety and Effectiveness of Inhaling Different Dosage Recombinant Human Interferon

Jiefeng Luo, Mengting Yang, Linan Zeng, Xiangcheng Pan, Dan Liu, Sha Diao, Liang Huang, Ting Chen, Zhi-Jun Jia, Guo Cheng and 2 more

Open access · hybridAbstract read
In one paragraph

Article in Evidence-based complementary and alternative medicine : eCAM, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.5field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 1 institution in 1 country.

Jiefeng LuoWest China School of Pharmacy, Sichuan University, Chengdu, China.ORCID https://orcid.org/0000-0001-9658-5100
Mengting YangDepartment of Pharmacy, West China Second University Hospital, Sichuan University, Chengdu, China.
Linan ZengDepartment of Pharmacy, West China Second University Hospital, Sichuan University, Chengdu, China.
Xiangcheng PanWest China School of Pharmacy, Sichuan University, Chengdu, China.ORCID https://orcid.org/0000-0001-8499-6623
Dan LiuWest China School of Pharmacy, Sichuan University, Chengdu, China.ORCID https://orcid.org/0000-0001-8004-2056
Sha DiaoDepartment of Pharmacy, West China Second University Hospital, Sichuan University, Chengdu, China.
Liang HuangDepartment of Pharmacy, West China Second University Hospital, Sichuan University, Chengdu, China.
Ting ChenDepartment of Pediatrics, West China Second Hospital, Sichuan University, Chengdu, China.
Zhi-Jun JiaWest China School of Pharmacy, Sichuan University, Chengdu, China.ORCID https://orcid.org/0000-0002-5143-4875
Guo ChengKey Laboratory of Birth Defects and Related Diseases of Women and Children, Sichuan University, Ministry of Education, Chengdu, China.
Qin YuKey Laboratory of Birth Defects and Related Diseases of Women and Children, Sichuan University, Ministry of Education, Chengdu, China.
Lingli ZhangDepartment of Pharmacy, West China Second University Hospital, Sichuan University, Chengdu, China.ORCID https://orcid.org/0000-0003-0872-5615
Sichuan University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Purpose: To systematically evaluate the safety and effectiveness of different dosages of recombinant human interferon Methods: 7 databases, including PubMed, EMBASE, Cochrane Library, Web of Science, CNKI, Wanfang Database, and VIP, were searched. The search time was from their inception dates to March 28, 2022. A randomized controlled trial (RCT) of 2 Results: A total of 13 RCTs with 1719 children were included. The meta-analysis results showed that the high dosage group was significantly shorter than the low dosage group of the duration of hospital stays (MD = -0.40, 95%CI (-0.73, -0.07), Conclusions: Compared with low dosage IFN

Identifiers

PMID35529920
PMCPMC9068289
OpenAlexW4225013340

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.